Trials / Completed
CompletedNCT00701259
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of Fourteen Day Treatment With Lansoprazole 15 mg or 30 mg Once a Day in Frequent Nighttime Heartburn
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 852 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg or 30 mg administered once a day in preventing frequent nighttime heartburn.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lansoprazole | Lansoprazole 15 mg once per day for 14 days |
| DRUG | Lansoprazole | Lansoprazole 30 mg once per day for 14 days |
| DRUG | placebo |
Timeline
- Start date
- 2007-01-01
- Completion
- 2007-08-01
- First posted
- 2008-06-19
- Last updated
- 2010-01-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00701259. Inclusion in this directory is not an endorsement.